Emavusertib hydrochloride is under clinical development by Curis and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Emavusertib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Emavusertib hydrochloride overview

Emavusertib hydrochloride is under development for the treatment of diffuse large B cell lymphomas, relapsed or refractory follicular lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia., mantle cell lymphoma, primary CNS lymphoma, secondary CNS lymphoma non-Hodgkin lymphomas such as Waldenstrom macroglobulinemia and marginal zone lymphoma, hematologic malignancies, gastric cancer, pancreatic ductal adenocarcinoma, metastatic melanoma, esophageal cancer and adenocarcinoma of the gastroesophageal junction, non-Hodgkin lymphomas such as myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) and chronic myelocytic leukemia (CML, chronic myeloid leukemia). It is a small molecule administered orally. The drug candidate is a triple target inhibitor interleukin-1 receptor-associated kinase-4 (IRAK-4), FLT3 (FMS like tyrosine kinase 3) and CLK (CDC-like kinase). It was also under development for the treatment of rheumatoid arthritis and relapsed or refractory acute myelocytic leukemia.

Curis overview

Curis is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating cancers with substantial unmet medical need. The company’s lead product Erivedge has been developed in collaboration with F. Hoffmann-La Roche Ltd and Genentech, which is commercialized for the treatment of advanced basal cell carcinoma (BCC). The product is approved for use in patients with advanced BCC in the US, European Union (EU), Australia and several other countries. The company has four drug candidates in development, Fimepinostat (previously CUDC-907) for treating diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-170 for advanced solid tumors or lymphoma; CA-4948 for treating non-Hodgkin lymphomas, and CI-8993 a human IgG1 kappa monoclonal antibody directed against VISTA including PD-1 and PD-L1 for treatment of cancer. Curtis is headquartered in Lexington, Massachusetts, the US.

For a complete picture of Emavusertib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.